If you are considering prostate cancer surgery, you may hear your surgeon discuss nerve-sparing. This means trying to preserve the delicate nerves that run alongside the prostate and play an important role in erectile function. At the same time, your surgeon must ensure that the cancer is removed as safely as possible.
The NeuroSAFE technique was developed to help make this decision more precise. During the operation, a rapid form of pathology called frozen-section analysis is used to examine tissue close to the nerve bundles. This allows your surgical team to receive important information while the procedure is still taking place.
This is important because the nerves sit very close to the prostate. NeuroSAFE gives your surgeon real-time feedback about whether cancer is present near the surgical margin. If it is safe to do so, more nerve tissue may be preserved, while areas that appear too close to the cancer can be removed to prioritise cancer control.
What Does NeuroSAFE Mean?
NeuroSAFE stands for neurovascular structure-adjacent frozen-section examination. Although the name sounds complex, the idea behind it is relatively straightforward. If you are considering prostate cancer surgery, NeuroSAFE is designed to help your surgeon make more informed decisions about nerve-sparing.
During radical prostatectomy, your surgeon removes the prostate and sends carefully selected tissue from the area next to the nerve bundles for immediate pathology assessment. The tissue is examined while you are still under anaesthetic, allowing important information to become available during the procedure itself.
This real-time assessment helps your surgeon adapt the operation when necessary. If the surgical margin is clear, nerve preservation may continue. If cancer is found close to the margin, your surgeon may remove additional tissue from that side to help ensure the cancer is treated safely.
Why Was NeuroSAFE Developed?
NeuroSAFE was developed because nerve-sparing decisions during prostate cancer surgery can be challenging. If you are having surgery, your surgeon wants to preserve erectile function where it is safe to do so. At the same time, they must avoid leaving cancer behind.
Before surgery, your surgeon uses MRI scans, biopsy results, PSA levels, clinical examination, and clinical experience to plan the operation. These tools provide valuable information, but they cannot always show microscopic cancer cells at the edge of the prostate. This can make some nerve-sparing decisions less certain.
NeuroSAFE adds another layer of information during the operation itself. By examining tissue close to the nerve bundles while you are still under anaesthetic, it helps your surgeon assess whether nerve preservation is safe. This allows your treatment team to balance cancer control and quality-of-life outcomes more precisely.
What Is Nerve-Sparing Prostate Surgery?
Nerve-sparing prostate surgery aims to preserve the neurovascular bundles that run alongside the prostate. These bundles contain nerves that play an important role in erectile function. If you are considering prostate cancer surgery, preserving these nerves may help improve your chances of maintaining erections after treatment.
The European Association of Urology notes that preserving the neurovascular bundles during radical prostatectomy can help protect erectile function when it is safe to do so. Whether this is possible for you depends on the location and extent of your cancer. Cancer control must always remain the priority.
Nerve-sparing can be performed on one side of the prostate or on both sides. Your surgeon will decide which approach is appropriate based on your MRI findings, biopsy results, and the position of the cancer. The goal is to preserve as much function as possible without compromising cancer clearance.
Why Are the Nerves at Risk During Surgery?
The nerves involved in erections lie extremely close to the outer surface of the prostate. Because of their position, they can be affected during prostate removal. If you are having surgery, protecting these nerves can be challenging when the cancer is located near them.
Patient information from BAUS explains that these nerves form delicate strands around the prostate and can only be preserved when the cancer has not reached the layer where they lie. This means your surgeon must carefully assess whether nerve preservation is safe in your particular case.
For this reason, nerve-sparing is not simply a technical preference. The decision involves balancing your future quality of life with the need to remove the cancer effectively. Your surgeon will recommend the approach that offers the safest combination of cancer control and functional preservation for you.
What Is the Main Goal of NeuroSAFE?
The main goal of NeuroSAFE is to maximise nerve preservation without compromising cancer control. If you are undergoing prostate cancer surgery, the technique gives your surgeon additional information to help decide whether tissue next to the prostate can be preserved safely. This can support more confident nerve-sparing decisions during the operation.
When the nerve-adjacent surgical margin is clear, your surgeon may be able to preserve more tissue and avoid unnecessary removal of structures that contribute to erectile function. If cancer is found at the margin, additional tissue can be removed immediately while you are still under anaesthetic. This helps reduce the risk of leaving cancer behind.
What makes NeuroSAFE different is that it provides real-time feedback during surgery. Rather than relying only on pre-operative planning, your surgeon can assess the findings as the procedure progresses. This allows the surgical plan to be refined based on information obtained during the operation itself.
How Does NeuroSAFE Work Step by Step?
NeuroSAFE begins after your surgeon has removed the prostate during radical prostatectomy. The tissue from areas next to the neurovascular bundles is carefully marked and prepared before being sent to the pathology team. This step is important because it helps the pathologist identify exactly which area is being assessed.
The tissue is then rapidly frozen, cut into very thin sections, stained, and examined under a microscope. This process is known as intraoperative frozen-section analysis. While you are still under anaesthetic, the pathology team rapidly assesses whether cancer is present at the surgical margin near the nerve-sparing area.
The pathologist then reports the findings to your surgeon during the operation. If the margin is clear, nerve preservation may continue as planned. If cancer is found at the margin, your surgeon may decide to remove additional tissue from that side. This allows your treatment plan to be adjusted in real time based on the pathology results.
What Is Frozen-Section Pathology?
Frozen-section pathology is a rapid method of examining tissue while an operation is still taking place. If you are having prostate cancer surgery, this technique allows the pathology team to provide important information to your surgeon before the procedure is finished. It is designed to answer a specific surgical question rather than replace the final pathology report.
In the NeuroSAFE process, the key question is whether cancer has reached the surgical margin next to the nerve bundle. This is an important area because your surgeon is trying to preserve function where possible while also ensuring that the cancer is removed safely. The findings can help guide decisions during the operation.
You should understand that frozen-section analysis is only one part of the assessment. After surgery, the entire prostate is examined using more detailed laboratory techniques. While NeuroSAFE provides real-time guidance during your operation, the final pathology report gives the most complete picture of your cancer and the surgical outcome.
What Is a Surgical Margin?
A surgical margin is the outer edge of the tissue removed during an operation. After your prostate has been removed, pathologists examine these edges to see whether any cancer cells are present. This information helps your medical team assess how completely the cancer has been removed.
If cancer cells are found at the edge of the tissue, this is known as a positive surgical margin. This does not automatically mean that the cancer will return, but it is associated with a higher risk of biochemical recurrence and may influence follow-up or consideration of additional treatment.
In the NeuroSAFE technique, particular attention is paid to the margin next to the neurovascular bundles. By assessing this area during the operation, your surgeon can make more informed decisions about nerve preservation. This helps balance the goal of protecting function with the need to remove the cancer safely.
Why Cancer Control Still Comes First
NeuroSAFE is not designed to preserve nerves at any cost. If you are considering this technique, it is important to understand that the main goal remains removing the cancer safely. Nerve preservation is considered only when it does not increase the risk of leaving cancer behind.
If cancer is found at the nerve-adjacent margin during surgery, your surgeon may remove additional tissue from that side. This may mean that fewer nerves can be preserved, but it can improve the chances of achieving effective cancer clearance. The decision is always based on balancing function with safety.
Before your operation, you should understand that NeuroSAFE is a decision-support tool rather than a guarantee of nerve preservation. It gives your surgeon more information during surgery, but it does not change the priority of treating the cancer effectively. Your safety remains the most important consideration.
Who May Benefit From NeuroSAFE?
NeuroSAFE may be most useful when there is uncertainty about whether nerve-sparing surgery is safe. If you have a tumour close to one side of the prostate or imaging suggests that cancer may be near the prostate capsule, this technique can provide additional information during surgery.
Men who have good erections before surgery may be particularly interested in preserving nerve function where possible. However, your suitability for NeuroSAFE depends on several factors, including the location, grade, and stage of your cancer. Your overall risk profile also helps your surgeon decide whether nerve preservation is appropriate.
NeuroSAFE is not needed for every patient. If your cancer is clearly away from the nerves, the additional information may offer limited benefit. Similarly, if the cancer is too close to the nerves for safe preservation, your surgeon may prioritise wider removal to achieve better cancer control.
Does NeuroSAFE Guarantee Erectile Function Recovery?
No. NeuroSAFE does not guarantee that you will recover erectile function after prostate cancer surgery. If you are considering this technique, it is important to understand that preserving the nerves can improve the opportunity for recovery, but it cannot predict the exact outcome for you.
Your recovery depends on several factors, including your age, erections before surgery, overall health, diabetes, cardiovascular health, smoking history, medication use, and the quality of nerve preservation. Even when the nerves are successfully preserved, they may need time to recover after surgery.
It is helpful to view NeuroSAFE as a tool that supports better surgical decision-making. It can help your surgeon preserve nerves when it is safe to do so, but it cannot promise a specific level of erectile function after treatment. Your specialist should discuss realistic expectations based on your individual circumstances.
What Does the Evidence Say About NeuroSAFE?
Evidence for NeuroSAFE has grown over time, helping doctors understand how this technique may improve nerve-sparing decisions during prostate cancer surgery. If you are considering this approach, you should know that earlier studies suggested NeuroSAFE could increase the chance of nerve preservation without affecting important cancer safety outcomes in experienced centres.
A 2022 validation study reported that NeuroSAFE helped more men undergo unilateral and bilateral nerve-sparing surgery. The study found no negative effect on surgical margin status or biochemical recurrence, which may be reassuring if you are looking for a balance between preserving function and treating the cancer safely.
More recent research continues to support NeuroSAFE, but your outcome still depends on careful patient selection, surgical experience, and specialist pathology support. When you discuss this option with your surgeon, you should ask how their team uses NeuroSAFE and whether it is suitable for your individual cancer situation.
What Did the Recent Randomised Trial Show?
A major randomised trial compared NeuroSAFE-guided robot-assisted radical prostatectomy with standard robot-assisted radical prostatectomy. If you are considering prostate cancer surgery, these findings are important because the study showed improved functional outcomes after NeuroSAFE-guided surgery in men who had good erectile function before treatment.
Randomised trials provide stronger evidence than many observational studies because they help show whether a technique itself contributes to better results. This reduces the chance that differences are only due to patient selection or differences between treatment groups. For you, this means the evidence gives a clearer understanding of the potential value of NeuroSAFE.
The trial supported the idea that checking nerve-adjacent margins during surgery can help surgeons preserve function more safely when appropriate. If you are discussing surgical options, NeuroSAFE may be one factor your team considers when planning how to balance cancer control with your recovery goals.
Evidence Note
The NeuroSAFE PROOF trial randomised 404 men undergoing robot-assisted radical prostatectomy. NeuroSAFE increased bilateral nerve-sparing rates while improving erectile-function recovery without increasing positive surgical margins or compromising early cancer-control outcomes. However, longer follow-up is still needed to confirm oncological outcomes over many years.
What Have Reviews Found?
Earlier pooled evidence was reassuring and consistently showed higher nerve-sparing rates. However, most studies were observational and vulnerable to selection bias, so the results should not be presented as definitive proof of long-term oncological safety.
However, the review also highlighted limitations in the available evidence. If you are discussing NeuroSAFE with your surgeon, you should understand that research continues to develop and that outcomes may vary depending on patient selection, surgical experience, and pathology expertise.
The overall message is positive but needs to be interpreted carefully. NeuroSAFE can be a valuable tool for selected patients when your surgical team has the right experience and support systems in place. Your decision should be based on whether the technique fits your individual cancer characteristics and recovery goals.
What Happens If the NeuroSAFE Result Is Clear?
If your NeuroSAFE frozen-section result is clear, your surgeon may feel more confident that the nerve-adjacent margin is free of visible cancer. This can allow nerve preservation to continue on that side when it is considered safe. For you, this may support the goal of protecting erectile function while still focusing on cancer control.
However, a clear NeuroSAFE result does not mean that every possible cancer risk has been eliminated. It only means that the specific tissue area examined during the operation did not show cancer at the surgical margin. Your surgeon will still consider all other information from your diagnosis when making decisions.
After surgery, your removed prostate will undergo a complete pathology examination. Your final report will provide more detailed information about your tumour grade, stage, surgical margins, and other important features. This full assessment helps guide your ongoing follow-up and treatment planning.
What Happens If NeuroSAFE Finds Cancer near the Margin?
If your NeuroSAFE result shows cancer at the nerve-adjacent margin, your surgeon can remove additional tissue during the same operation. This is sometimes called secondary resection. For you, this means the surgical plan can be adjusted immediately rather than waiting for the final pathology report after surgery.
The aim of removing extra tissue is to reduce the chance of leaving cancer behind. This is one of the main advantages of checking the margin while your operation is still taking place. Your surgeon receives real-time information that can help guide the safest approach.
However, removing additional tissue may affect nerve preservation on that side. If you are considering NeuroSAFE, you should understand this possible trade-off before surgery. Your surgeon can explain how this decision may affect your cancer control and your chances of preserving erectile function.
What Is Bilateral Nerve-Sparing?
Bilateral nerve-sparing means preserving both nerve bundles that run alongside the prostate during surgery. If you are suitable for this approach, it may offer the best chance of protecting erectile function after treatment. However, it can only be considered when your surgeon believes it is safe from a cancer-control perspective.
NeuroSAFE may help your surgeon make bilateral nerve-sparing decisions with greater confidence. If your pre-operative scans and biopsy results do not provide a clear answer, the additional information during surgery can help guide the decision. This may increase the opportunity for nerve preservation in selected patients.
However, bilateral nerve-sparing is not the right option for every man. If your cancer is close to one or both nerve bundles, your surgeon may recommend removing more tissue to improve cancer clearance. Your treatment plan should always prioritise safe cancer removal while considering your recovery goals.
What Is Unilateral Nerve-Sparing?
Unilateral nerve-sparing means preserving one nerve bundle while removing tissue more widely on the other side. If you have cancer that appears closer to one side of the prostate, your surgeon may consider this approach to balance cancer control with the possibility of preserving function.
NeuroSAFE can help your surgeon assess the side where nerve-sparing is being considered. If your margin result is clear, nerve preservation may continue on that side. If cancer is found near the margin, your surgeon may remove additional tissue to improve cancer safety.
This approach may still provide functional benefits compared with removing both nerve bundles. Your suitability depends on factors such as your cancer location, tumour characteristics, and erectile function before surgery. Your surgeon will discuss whether unilateral nerve-sparing is appropriate for you.
How Does MRI Help Plan NeuroSAFE?
MRI is an important tool before prostate cancer surgery because it helps your surgeon see where the tumour is located. If you are considering nerve-sparing surgery, the scan can show whether the cancer is near the prostate edge or close to areas where nerves might be preserved.
- Guiding Surgical Planning: MRI helps your surgeon decide if nerve-sparing is likely to be safe and whether NeuroSAFE could add value during the operation.
- Combined Assessment: Your MRI results are considered alongside PSA levels, biopsy grade, examination findings, and overall health to create a complete picture.
- Limitations of MRI: MRI cannot detect every microscopic area of cancer, so it is not the sole guide for surgery.
- NeuroSAFE Adds Extra Safety: During surgery, NeuroSAFE checks the nerve-adjacent margin in real time, allowing your surgeon to adjust the plan if needed.
Overall, MRI helps plan a safer, more personalised approach to nerve-sparing surgery, while NeuroSAFE provides additional intraoperative guidance to protect nerve function.
Does NeuroSAFE Replace Pre-Operative Planning?
No, NeuroSAFE does not replace careful planning before prostate cancer surgery. If you are considering this technique, you should understand that it works as part of a wider treatment pathway rather than as a replacement for proper assessment. Good preparation remains essential for achieving the best possible outcome.
Before your operation, your specialist will review your MRI results, biopsy findings, PSA level, cancer risk category, urinary function, erectile function, and overall health. This information helps your team decide whether surgery and nerve-sparing are suitable for you.
NeuroSAFE then provides additional information while you are in the operating theatre. It allows your surgeon to make adjustments based on real-time pathology findings. However, it does not replace accurate diagnosis, cancer staging, or careful surgical planning before your procedure.
UK Guidance Note
NICE NG131 does not make a specific recommendation that NeuroSAFE should be used during radical prostatectomy. It supports informed treatment discussions and recommends access to specialist services for urinary incontinence and erectile dysfunction after radical prostate cancer treatment.
The European Association of Urology recommends offering nerve-sparing surgery when there is a low risk of extracapsular disease on the relevant side. Its current prostate cancer guideline discusses NeuroSAFE as an intraoperative resource that may help surgeons balance nerve preservation with surgical-margin assessment.
NeuroSAFE should therefore be viewed as an additional decision-support technique rather than a replacement for MRI, biopsy assessment, surgical planning or final pathology.
Why the Pathology Team Matters
The pathology team plays a crucial role in the success of NeuroSAFE. If you are considering this technique, you should understand that it depends not only on the surgeon but also on how quickly and accurately the tissue can be processed and assessed during your operation.
The tissue must be carefully prepared, correctly orientated, and examined while surgery is still ongoing. This requires experience, organisation, and clear communication between your surgeon and the pathologist. Without good coordination, the information provided by NeuroSAFE may be less reliable.
For you, this means NeuroSAFE is more than just a surgical technique. It is a coordinated process involving surgeons, pathologists, and the wider operating team. The experience of the whole team can influence how effectively the technique supports decisions about nerve preservation and cancer control.
Does NeuroSAFE Add Time to Surgery?
NeuroSAFE can add extra time to your operation because the tissue needs to be prepared, processed, and examined while surgery is taking place. The exact time added can vary depending on the hospital process, the complexity of your case, and the amount of tissue that needs assessment.
For suitable patients, this additional time may be worthwhile if it helps your surgeon make safer decisions about nerve preservation. If you are considering NeuroSAFE, you should understand that the goal is not to extend the operation unnecessarily. The purpose is to provide useful information when the decision between preserving nerves and removing more tissue is difficult.
Your surgeon can explain whether NeuroSAFE is appropriate for your situation and how it may affect your procedure. The decision should be based on your cancer characteristics, treatment goals, and whether the additional information is likely to provide meaningful benefit for you.
Are There Risks or Limitations?
The risks associated with NeuroSAFE are mainly linked to the wider prostate cancer operation rather than the technique itself. If you are considering NeuroSAFE, you should understand that it is designed to guide surgical decisions rather than act as a separate treatment. In some cases, the findings may lead your surgeon to remove more tissue to improve cancer safety.
One limitation is that NeuroSAFE requires specialist pathology support, accurate tissue handling, and an experienced surgical team. The frozen-section assessment only examines specific areas during the operation and does not replace the full final pathology report after surgery.
You should also know that NeuroSAFE may not change the surgical plan if your cancer is clearly too close to the nerves for safe preservation. The greatest value of the technique is when your surgeon is uncertain whether nerve-sparing can be performed safely. In these situations, NeuroSAFE can provide extra information to support your treatment decision.
How Does NeuroSAFE Fit With Robotic Surgery?
NeuroSAFE is often discussed alongside robotic prostatectomy because robotic surgery allows your surgeon to perform precise dissection around the prostate. If you are considering robotic surgery, you may benefit from understanding that the technology provides magnified three-dimensional vision and improved instrument control during the procedure.
However, the robot does not make decisions about cancer safety by itself. Your surgeon still needs to decide how much tissue should be removed and whether nerve preservation is appropriate. NeuroSAFE adds real-time pathology information that can support these decisions during the operation.
For selected patients, the combination of robotic surgery and NeuroSAFE can be valuable. The robotic system helps your surgeon perform careful dissection, while NeuroSAFE provides additional information about whether preserving the nerves is safe. Together, these tools can support a more personalised approach to prostate cancer surgery.
How Is NeuroSAFE Different From Standard Nerve-Sparing?
In standard nerve-sparing surgery, your surgeon decides how much nerve tissue can be preserved using information available before and during the operation. If you are considering prostate cancer surgery, this decision is based on factors such as your MRI findings, biopsy results, cancer location, and what your surgeon sees during the procedure.
With NeuroSAFE, your surgeon also receives frozen-section pathology information from the nerve-adjacent margin. This provides additional evidence during the operation and may help guide decisions about whether nerve preservation is safe on each side.
This does not mean that standard nerve-sparing surgery is unsafe or ineffective. It means NeuroSAFE may offer extra information in selected situations where you and your surgeon are trying to balance two important goals: preserving function and achieving effective cancer control.
NeuroSAFE vs Standard Nerve-Sparing
| Feature | Standard nerve-sparing | NeuroSAFE-guided surgery |
| Surgical planning | MRI + biopsy | MRI + biopsy + intraoperative frozen section |
| Pathology during surgery | No | Yes |
| Margin assessment | Final pathology only | Real-time frozen section |
| Bilateral nerve-sparing | Based on pre-operative judgement | Increased in the phase 3 trial; individual oncological suitability remains essential. |
| Cancer control | Standard approach | Early findings are broadly reassuring, but longer randomised follow-up is needed |
| Operating time | Standard | Usually slightly longer |
| Pathology support required | No | Specialist frozen-section service |
What Should You Ask Your Surgeon?
You should ask your surgeon whether your cancer appears suitable for nerve-sparing and whether NeuroSAFE could provide additional value in your case. If you are considering this technique, understanding why it may or may not be recommended for you can help you feel more confident about your treatment plan.
It is also important to ask what would happen if the frozen-section result shows cancer at the margin. You should understand how this finding could change the surgical approach and whether additional tissue may need to be removed during the operation.
You may also want to discuss your expected recovery after surgery. Ask about continence recovery, erectile function recovery, rehabilitation support, and PSA follow-up. NeuroSAFE can help guide surgical decisions, but it is only one part of your overall prostate cancer treatment and recovery pathway.
Who Might Not Be Suitable for NeuroSAFE?
NeuroSAFE may be less useful if your cancer clearly requires wider removal of tissue on one or both sides of the prostate. In this situation, preserving the nerves may not be considered safe even with additional frozen-section information. Your surgeon will always prioritise effective cancer removal.
The technique may also provide less functional benefit if your erectile function was already significantly reduced before surgery. However, your cancer-control needs remain important regardless of your baseline function. Your surgeon can explain whether nerve preservation is likely to offer meaningful benefits for you.
Suitability for NeuroSAFE depends on your complete clinical picture, including your cancer location, stage, risk level, and personal goals. There is no single rule that applies to everyone. The decision should be personalised to your individual situation.
What Recovery Support Is Needed After NeuroSAFE?
Even if NeuroSAFE helps your surgeon preserve nerves, recovery after prostate surgery still takes time. If you have nerve-sparing surgery, the nerves can still be affected by stretching, handling, or temporary changes during the operation. Your erectile function may improve gradually over months or even longer.
You may be offered erectile rehabilitation to support your recovery. This can include treatments such as tablets, vacuum devices, injections, or other options depending on your situation. Your specialist will explain which approaches may be suitable for you and guide you through the recovery process.
Urinary recovery is also an important part of your recovery after prostatectomy. You should follow advice on pelvic floor exercises, catheter care, and follow-up appointments. NeuroSAFE can support nerve preservation decisions, but your ongoing recovery plan is equally important for achieving the best possible outcome.
Post-Operative Recovery After NeuroSAFE-Guided Prostate Surgery
| Recovery Aspect | Key Points | Patient Considerations |
| Erectile Function | Nerve preservation may improve chances of recovery | Recovery depends on age, baseline erectile function, overall health, and extent of nerve-sparing |
| Urinary Continence | Pelvic floor exercises recommended | May involve physiotherapist assessment; recovery timeline varies |
| Rehabilitation Support | Use of PDE5 inhibitors, vacuum devices, injections if needed | Tailored by specialist based on individual recovery progress |
| Follow-Up Appointments | Regular PSA monitoring and clinical review | Ensures early detection of recurrence and assessment of functional recovery |
| Pain Management | Guidance provided on post-op analgesia | Helps maintain mobility and comfort during early recovery |
| Activity and Lifestyle | Gradual return to normal activities recommended | Avoid heavy lifting or strenuous exercise initially; follow surgeon’s advice |
| Long-Term Monitoring | Ongoing functional and oncological review | Supports quality-of-life outcomes and cancer control |
Clinical Tip: Plan Erectile and Continence Rehabilitation Separately
Erectile-function and urinary-continence recovery require different forms of support after prostatectomy.
Erectile rehabilitation may involve PDE5 inhibitor tablets, a vacuum erection device, penile injections or other specialist treatments according to your health and response. These treatments can support sexual rehabilitation, but they cannot guarantee recovery of spontaneous erections.
Pelvic-floor muscle exercises are primarily used to support urinary continence. Correct technique is important, and you may benefit from assessment by a pelvic-health physiotherapist or specialist continence service.
Ask your surgical team when rehabilitation should begin, which treatments are suitable for you and what outcomes are realistic based on your age, baseline function and degree of nerve preservation.
Choosing Specialist NeuroSAFE Care
Because NeuroSAFE involves close coordination between surgery, pathology, and recovery support, choosing the right specialist team is important. If you are considering this technique, you should feel that the discussion is focused on your individual cancer diagnosis and your personal treatment goals.
A specialist consultation for NeuroSAFE prostate surgery in London should include a review of your MRI findings, biopsy grade, cancer location, and whether nerve-sparing is likely to be suitable for you. You should also discuss realistic expectations for recovery, including urinary control and erectile function.
A good consultation should not simply focus on promoting the technique. You should understand whether NeuroSAFE is appropriate for your situation, what benefits it may offer, and what its limitations are. Your surgeon should also explain how cancer safety will remain the priority throughout your treatment.
What Is the Main Message About NeuroSAFE?
The NeuroSAFE technique is an advanced approach that helps surgeons make more informed nerve-sparing decisions during prostate cancer surgery. If you are considering this option, it is important to understand that its main purpose is to support safer decision-making while aiming to protect your quality of life.
The key strength of NeuroSAFE is the real-time information it provides during surgery. Instead of relying only on pre-operative scans and predictions, your surgeon can assess the nerve-adjacent margin while the operation is taking place. This allows the surgical plan to be adjusted if needed based on the findings.
NeuroSAFE does not guarantee that you will preserve erections or eliminate every cancer risk. Its value is in helping your surgeon balance two important goals: removing your cancer effectively and preserving function wherever it is safe to do so. The best results depend on careful patient selection, surgical experience, and a personalised treatment approach.
Myth vs Fact
| Myth | Fact |
| NeuroSAFE guarantees erections. | No. It improves opportunities for nerve preservation but cannot guarantee recovery. |
| NeuroSAFE is more important than cancer removal. | Cancer control always remains the priority. |
| Everyone should have NeuroSAFE. | It is most useful in selected patients where nerve preservation is uncertain. |
| MRI makes NeuroSAFE unnecessary. | MRI is essential but cannot detect every microscopic cancer focus. |
| Frozen section replaces final pathology. | Final pathology remains the definitive assessment. |
| NeuroSAFE is a separate operation. | It is an additional pathology technique performed during prostatectomy. |
| A clear NeuroSAFE result proves that every surgical margin is negative. | NeuroSAFE assesses specified nerve-adjacent margins during surgery. The complete prostate still requires final pathology. |
Key Takeaways
- NeuroSAFE uses frozen-section pathology during surgery.
- It helps guide safer nerve-sparing decisions.
- The technique may increase the opportunity for bilateral nerve preservation in carefully selected patients.
- Cancer control remains the main priority.
- Frozen-section analysis complements but does not replace final pathology.
- NeuroSAFE is most useful in carefully selected patients.
- Functional recovery still depends on age, baseline erectile function and overall health.
- A phase 3 randomised trial supports functional benefits, while longer oncological follow-up is still needed.
- The phase 3 trial improved 12-month erectile-function outcomes and early continence recovery, but long-term cancer-control follow-up remains necessary.
FAQs:
1. What is the NeuroSAFE technique in prostate cancer surgery?
The NeuroSAFE technique is an intraoperative frozen-section pathology method used during radical prostatectomy. It helps surgeons assess tissue close to the nerve bundles while the operation is still taking place, supporting safe nerve preservation where appropriate.
2. How does NeuroSAFE help preserve erectile function?
NeuroSAFE provides real-time information about whether cancer is present near the nerve bundles. If the designated frozen section is negative, the initially preserved nerve bundle may remain in place without secondary resection.
3. Does NeuroSAFE guarantee erectile function recovery?
No. NeuroSAFE may improve the chances of nerve preservation, but erectile function recovery also depends on factors such as age, pre-operative erectile function, overall health, and the extent of nerve-sparing that is possible.
4. Is NeuroSAFE suitable for every prostate cancer patient?
No. NeuroSAFE is most useful when there is uncertainty about whether nerve-sparing can be performed safely. The suitability of the technique depends on tumour location, cancer stage, MRI findings, and individual patient factors.
5. What happens if NeuroSAFE detects cancer at the surgical margin?
If cancer is found at the nerve-adjacent margin, the surgeon can remove additional tissue during the same operation. This is intended to reduce concern about a positive nerve-adjacent margin, although secondary resection may reduce nerve preservation on that side.
6. Does NeuroSAFE affect cancer control?
Current evidence suggests that NeuroSAFE can increase nerve-sparing rates without compromising key cancer-control outcomes in appropriately selected patients treated by experienced teams.
7. Is NeuroSAFE only available during robotic prostate surgery?
NeuroSAFE is most commonly used alongside robotic-assisted radical prostatectomy, but the technique itself is based on frozen-section pathology rather than the surgical platform used.
8. Does NeuroSAFE replace MRI scans and pre-operative planning?
No. MRI scans, biopsy results, PSA levels, and clinical assessment remain essential parts of treatment planning. NeuroSAFE provides additional information during surgery and complements, rather than replaces, pre-operative assessment.
9. Does NeuroSAFE make the operation longer?
NeuroSAFE usually adds operating time because tissue must be prepared and examined during surgery. The amount varies according to the pathology workflow and the team’s experience.
10. What should you ask your surgeon about NeuroSAFE?
You should ask whether your cancer appears suitable for nerve-sparing, whether NeuroSAFE is available and appropriate in your case, how the results could influence the operation, and what outcomes you can realistically expect regarding cancer control, continence, and erectile function recovery.
Final Thoughts: Understanding the Role of NeuroSAFE in Modern Prostate Surgery
The NeuroSAFE technique has helped make nerve-sparing prostate surgery more precise by providing real-time information during the operation. By assessing tissue close to the nerve bundles while surgery is still taking place, it can help surgeons preserve nerves when it is safe to do so without losing focus on effective cancer control. This approach aims to support both cancer treatment and quality-of-life outcomes.
Although NeuroSAFE is not suitable for every patient and cannot guarantee erectile function recovery, growing evidence suggests it can be valuable in carefully selected cases. Although NeuroSAFE improves intraoperative decision-making, the overall success of surgery still depends on accurate diagnosis, careful patient selection, experienced surgeons and comprehensive postoperative rehabilitation.
If you would like to find out whether advanced NeuroSAFE prostate surgery in London could be appropriate for your situation, an experienced prostate cancer surgeon can explain how the technique may fit into your treatment plan and what outcomes you may realistically expect based on your individual diagnosis and cancer characteristics.
References:
- National Institute for Health and Care Excellence (NICE) (2019, last updated 2021; reviewed 2025). Prostate cancer: diagnosis and management. NICE guideline NG131. Available at: https://www.nice.org.uk/guidance/ng131
- NHS (no date). Treatment for prostate cancer. Available at: https://www.nhs.uk/conditions/prostate-cancer/treatment/
- Prostate Cancer UK (no date). Surgery: radical prostatectomy. Available at: https://prostatecanceruk.org/prostate-information-and-support/treatments/surgery
- European Association of Urology (EAU) (2026). EAU Guidelines on Prostate Cancer: Treatment. Available at: https://uroweb.org/guidelines/prostate-cancer/chapter/treatment
- Dinneen E, et al. (2025). Effect of NeuroSAFE-guided robot-assisted radical prostatectomy versus standard robot-assisted radical prostatectomy on erectile function and urinary continence in patients with localised prostate cancer: the NeuroSAFE PROOF phase 3 trial. The Lancet Oncology. Available at: https://pubmed.ncbi.nlm.nih.gov/40147459/
- Kroon LJ, et al. (2025). Neurovascular structure-adjacent frozen-section examination during radical prostatectomy: a systematic review and meta-analysis. European Urology Oncology. Available at: https://pubmed.ncbi.nlm.nih.gov/39730246/
- van der Slot MA, et al. (2022). NeuroSAFE in radical prostatectomy increases the rate of nerve-sparing surgery without affecting oncological outcome. BJU International. Available at: https://pubmed.ncbi.nlm.nih.gov/35536200/
- Noël J, et al. (2022). NeuroSAFE robot-assisted radical prostatectomy: outcomes from 500 consecutive UK cases. Journal of Robotic Surgery. Available at: https://pubmed.ncbi.nlm.nih.gov/34716876/